Minerva Neurosciences Announces Update on its New Drug Application (NDA) for ... - BioSpace

Retrieved on: 2022-12-29 11:08:11

Tags for this article:

Psychiatry

Schizophrenia

Abnormal psychology

Psychology

Alogia

Forward-looking statement

Anhedonia

Antipsychotic

Food and Drug Administration

Avolition

Causes of schizophrenia

Minerva Neurosciences Inc

Click the tags to see associated articles and topics

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for ... - BioSpace. View article details on HISWAI: https://www.biospace.com/article/releases/minerva-neurosciences-announces-update-on-its-new-drug-application-nda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia/

Excerpt

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia ...

Article found on: www.biospace.com

View Original Article